Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2023

08-09-2022 | Special Section: Methodologies for Meaningful Change

“From Where I Stand”: using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ)

Auteurs: Susan J. Bartlett, Vivian P. Bykerk, Orit Schieir, Marie-France Valois, Janet E. Pope, Gilles Boire, Carol Hitchon, Glen Hazlewood, Louis Bessette, Edward Keystone, Carter Thorne, Diane Tin, Clifton O. Bingham III, CATCH Investigators

Gepubliceerd in: Quality of Life Research | Uitgave 5/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The Rheumatoid Arthritis Flare Questionnaire (RA-FQ) is a patient-reported measure of disease activity in RA. We estimated minimal and meaningful change from the perspective of RA patients, physicians, and using a disease activity index.

Methods

Data were from 3- to 6-month visits of adults with early RA enrolled in the Canadian Early Arthritis Cohort. Participants completed the RA-FQ, the Patient Global Assessment of RA, and the Patient Global Change Impression at consecutive visits. Rheumatologists recorded joint counts and MD Global. Clinical Disease Activity Index (CDAI) scores were computed. We compared mean RA-FQ change across categories using patients, physicians, and CDAI anchors.

Results

The 808 adults were mostly white (84%) women (71%) with a mean age of 55 and moderate-high disease activity (85%) at enrollment. At V2, 79% of patients classified their RA as changed; 59% were better and 20% were worse. Patients reporting they were a lot worse had a mean RA-FQ increase of 8.9 points, whereas those who were a lot better had a -6.0 decrease. Minimal worsening and improvement were associated with a mean 4.7 and − 1.8 change in RA-FQ, respectively, while patients rating their RA unchanged had stable scores. Physician and CDAI classified more patients as worse than patients, and minimal and meaningful RA-FQ thresholds differed by group.

Conclusion

Thresholds to identify meaningful change vary by anchor used. These data offer new evidence demonstrating robust psychometric properties of the RA-FQ and offer guidance about improvement or worsening, supporting its use in RA care, research, and decision-making.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M., & Gabriel, S. E. (2010). Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis and Rheumatism, 62, 1576–1582.PubMedPubMedCentralCrossRef Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M., & Gabriel, S. E. (2010). Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis and Rheumatism, 62, 1576–1582.PubMedPubMedCentralCrossRef
2.
go back to reference Myasoedova, E., Davis, J. M., 3rd., Crowson, C. S., & Gabriel, S. E. (2010). Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality. Current Rheumatology Reports, 12, 379–385.PubMedCrossRef Myasoedova, E., Davis, J. M., 3rd., Crowson, C. S., & Gabriel, S. E. (2010). Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality. Current Rheumatology Reports, 12, 379–385.PubMedCrossRef
3.
go back to reference Bartlett, S. J., Hewlett, S., Bingham, C. O., 3rd., Woodworth, T. G., Alten, R., Pohl, C., Choy, E. H., Sanderson, T., Boonen, A., Bykerk, V., et al. (2012). Identifying core domains to assess flare in rheumatoid arthritis: An OMERACT international patient and provider combined Delphi consensus. Annals of the Rheumatic Diseases, 71, 1855–1860.PubMedCrossRef Bartlett, S. J., Hewlett, S., Bingham, C. O., 3rd., Woodworth, T. G., Alten, R., Pohl, C., Choy, E. H., Sanderson, T., Boonen, A., Bykerk, V., et al. (2012). Identifying core domains to assess flare in rheumatoid arthritis: An OMERACT international patient and provider combined Delphi consensus. Annals of the Rheumatic Diseases, 71, 1855–1860.PubMedCrossRef
4.
go back to reference Sanderson, T., Morris, M., Calnan, M., Richards, P., & Hewlett, S. (2010). Patient perspective of measuring treatment efficacy: The rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken), 62, 647–656.PubMedCrossRef Sanderson, T., Morris, M., Calnan, M., Richards, P., & Hewlett, S. (2010). Patient perspective of measuring treatment efficacy: The rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken), 62, 647–656.PubMedCrossRef
5.
go back to reference Gossec, L., Dougados, M., Rincheval, N., Balanescu, A., Boumpas, D. T., Canadelo, S., Carmona, L., Daures, J. P., de Wit, M., Dijkmans, B. A., et al. (2009). Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: A EULAR initiative. Annals of the Rheumatic Diseases, 68, 1680–1685.PubMedCrossRef Gossec, L., Dougados, M., Rincheval, N., Balanescu, A., Boumpas, D. T., Canadelo, S., Carmona, L., Daures, J. P., de Wit, M., Dijkmans, B. A., et al. (2009). Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: A EULAR initiative. Annals of the Rheumatic Diseases, 68, 1680–1685.PubMedCrossRef
6.
go back to reference Ward, M. M. (2022). Trends in permanent work disability associated with rheumatoid arthritis in the United States, 1999–2015. Arthritis Care Res (Hoboken), 74, 1321–1324.PubMedCrossRef Ward, M. M. (2022). Trends in permanent work disability associated with rheumatoid arthritis in the United States, 1999–2015. Arthritis Care Res (Hoboken), 74, 1321–1324.PubMedCrossRef
7.
go back to reference Bingham, C. O., III., Pohl, C., Woodworth, T. G., Hewlett, S. E., May, J. E., Rahman, M. U., Witter, J. P., Furst, D. E., Strand, C. V., Boers, M., & Alten, R. E. (2009). Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). Journal of Rheumatology, 36, 2335–2341.PubMedCrossRef Bingham, C. O., III., Pohl, C., Woodworth, T. G., Hewlett, S. E., May, J. E., Rahman, M. U., Witter, J. P., Furst, D. E., Strand, C. V., Boers, M., & Alten, R. E. (2009). Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). Journal of Rheumatology, 36, 2335–2341.PubMedCrossRef
8.
go back to reference Myasoedova, E., Chandran, A., Ilhan, B., Major, B. T., Michet, C. J., Matteson, E. L., & Crowson, C. S. (2016). The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Annals of the Rheumatic Diseases, 75, 560–565.PubMedCrossRef Myasoedova, E., Chandran, A., Ilhan, B., Major, B. T., Michet, C. J., Matteson, E. L., & Crowson, C. S. (2016). The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Annals of the Rheumatic Diseases, 75, 560–565.PubMedCrossRef
9.
go back to reference Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compan, M. V., Oliver, S., Schoels, M., et al. (2016). Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 75, 3–15.PubMedCrossRef Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compan, M. V., Oliver, S., Schoels, M., et al. (2016). Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 75, 3–15.PubMedCrossRef
10.
go back to reference Nikiphorou, E., Radner, H., Chatzidionysiou, K., Desthieux, C., Zabalan, C., van Eijk-Hustings, Y., Dixon, W. G., Hyrich, K. L., Askling, J., & Gossec, L. (2016). Patient global assessment in measuring disease activity in rheumatoid arthritis: A review of the literature. Arthritis Research & Therapy, 18, 251.CrossRef Nikiphorou, E., Radner, H., Chatzidionysiou, K., Desthieux, C., Zabalan, C., van Eijk-Hustings, Y., Dixon, W. G., Hyrich, K. L., Askling, J., & Gossec, L. (2016). Patient global assessment in measuring disease activity in rheumatoid arthritis: A review of the literature. Arthritis Research & Therapy, 18, 251.CrossRef
11.
go back to reference Prevoo, M. L., t’Hof, M. A., Kuper, H. H., van Leeuwen, M. A., van De Putte, L. B., & van Riel, P. L. (1995). Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism, 38, 44–48.PubMedCrossRef Prevoo, M. L., t’Hof, M. A., Kuper, H. H., van Leeuwen, M. A., van De Putte, L. B., & van Riel, P. L. (1995). Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism, 38, 44–48.PubMedCrossRef
12.
go back to reference Aletaha, D., & Smolen, J. (2005). The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology, 23, S100–S108.PubMed Aletaha, D., & Smolen, J. (2005). The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology, 23, S100–S108.PubMed
13.
go back to reference Oderda, G. M., & Balfe, L. M. (2011). Comparative effectiveness research (CER): A summary of AHRQ’s CER on therapies for rheumatoid arthritis. Journal of Managed Care Pharmacy, 17, S19–S24.PubMedCrossRef Oderda, G. M., & Balfe, L. M. (2011). Comparative effectiveness research (CER): A summary of AHRQ’s CER on therapies for rheumatoid arthritis. Journal of Managed Care Pharmacy, 17, S19–S24.PubMedCrossRef
14.
go back to reference Bingham, C. O., 3rd., Alten, R., Bartlett, S. J., Bykerk, V. P., Brooks, P. M., Choy, E., Christensen, R., Furst, D. E., Hewlett, S. E., Leong, A., et al. (2011). Identifying preliminary domains to detect and measure rheumatoid arthritis flares: Report of the OMERACT 10 RA Flare Workshop. Journal of Rheumatology, 38, 1751–1758.PubMedCrossRef Bingham, C. O., 3rd., Alten, R., Bartlett, S. J., Bykerk, V. P., Brooks, P. M., Choy, E., Christensen, R., Furst, D. E., Hewlett, S. E., Leong, A., et al. (2011). Identifying preliminary domains to detect and measure rheumatoid arthritis flares: Report of the OMERACT 10 RA Flare Workshop. Journal of Rheumatology, 38, 1751–1758.PubMedCrossRef
15.
go back to reference Bykerk, V. P., Lie, E., Bartlett, S. J., Alten, R., Boonen, A., Christensen, R., Furst, D. E., Hewlett, S., Leong, A. L., Lyddiatt, A., et al. (2014). Establishing a core domain set to measure rheumatoid arthritis flares: Report of the OMERACT 11 RA flare Workshop. Journal of Rheumatology, 41, 799–809.PubMedCrossRef Bykerk, V. P., Lie, E., Bartlett, S. J., Alten, R., Boonen, A., Christensen, R., Furst, D. E., Hewlett, S., Leong, A. L., Lyddiatt, A., et al. (2014). Establishing a core domain set to measure rheumatoid arthritis flares: Report of the OMERACT 11 RA flare Workshop. Journal of Rheumatology, 41, 799–809.PubMedCrossRef
16.
go back to reference Hewlett, S., Sanderson, T., May, J., Alten, R., Bingham, C. O., 3rd., Cross, M., March, L., Pohl, C., Woodworth, T., & Bartlett, S. J. (2012). “I’m hurting, I want to kill myself”: Rheumatoid arthritis flare is more than a high joint count–an international patient perspective on flare where medical help is sought. Rheumatology (Oxford), 51, 69–76.PubMedCrossRef Hewlett, S., Sanderson, T., May, J., Alten, R., Bingham, C. O., 3rd., Cross, M., March, L., Pohl, C., Woodworth, T., & Bartlett, S. J. (2012). “I’m hurting, I want to kill myself”: Rheumatoid arthritis flare is more than a high joint count–an international patient perspective on flare where medical help is sought. Rheumatology (Oxford), 51, 69–76.PubMedCrossRef
17.
go back to reference Bartlett, S. J., Barbic, S. P., Bykerk, V. P., Choy, E. H., Alten, R., Christensen, R., den Broeder, A., Fautrel, B., Furst, D. E., Guillemin, F., et al. (2017). Content and construct validity, reliability, and responsiveness of the rheumatoid arthritis flare questionnaire: OMERACT 2016 workshop report. Journal of Rheumatology, 44, 1536–1543.PubMedCrossRef Bartlett, S. J., Barbic, S. P., Bykerk, V. P., Choy, E. H., Alten, R., Christensen, R., den Broeder, A., Fautrel, B., Furst, D. E., Guillemin, F., et al. (2017). Content and construct validity, reliability, and responsiveness of the rheumatoid arthritis flare questionnaire: OMERACT 2016 workshop report. Journal of Rheumatology, 44, 1536–1543.PubMedCrossRef
18.
go back to reference Bartlett, S. J., Bykerk, V. P., Cooksey, R., Choy, E. H., Alten, R., Christensen, R., Furst, D. E., Guillemin, F., Halls, S., Hewlett, S., et al. (2015). Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: Report of the OMERACT 2014 RA flare group plenary. Journal of Rheumatology, 42, 2185–2189.PubMedCrossRef Bartlett, S. J., Bykerk, V. P., Cooksey, R., Choy, E. H., Alten, R., Christensen, R., Furst, D. E., Guillemin, F., Halls, S., Hewlett, S., et al. (2015). Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: Report of the OMERACT 2014 RA flare group plenary. Journal of Rheumatology, 42, 2185–2189.PubMedCrossRef
19.
go back to reference Wyrwich, K. W., Norquist, J. M., Lenderking, W. R., & Acaster, S. (2013). Methods for interpreting change over time in patient-reported outcome measures. Quality of Life Research, 22, 475–483.PubMedCrossRef Wyrwich, K. W., Norquist, J. M., Lenderking, W. R., & Acaster, S. (2013). Methods for interpreting change over time in patient-reported outcome measures. Quality of Life Research, 22, 475–483.PubMedCrossRef
20.
go back to reference Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials., 10, 407–415.PubMedCrossRef Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials., 10, 407–415.PubMedCrossRef
21.
go back to reference Bartlett, S. J., Gutierrez, A. K., Andersen, K. M., Bykerk, V. P., Curtis, J. R., Haque, U. J., Orbai, A. M., Jones, M. R., & Bingham, C. O., 3rd. (2022). Identifying minimal and meaningful change in a patient-reported outcomes measurement information system for rheumatoid arthritis: Use of multiple methods and perspectives. Arthritis Care Res (Hoboken), 74, 588–597.PubMedCrossRef Bartlett, S. J., Gutierrez, A. K., Andersen, K. M., Bykerk, V. P., Curtis, J. R., Haque, U. J., Orbai, A. M., Jones, M. R., & Bingham, C. O., 3rd. (2022). Identifying minimal and meaningful change in a patient-reported outcomes measurement information system for rheumatoid arthritis: Use of multiple methods and perspectives. Arthritis Care Res (Hoboken), 74, 588–597.PubMedCrossRef
22.
go back to reference Wells, G., Beaton, D., Shea, B., Boers, M., Simon, L., Strand, V., Brooks, P., & Tugwell, P. (2001). Minimal clinically important differences: Review of methods. Journal of Rheumatology, 28, 406–412.PubMed Wells, G., Beaton, D., Shea, B., Boers, M., Simon, L., Strand, V., Brooks, P., & Tugwell, P. (2001). Minimal clinically important differences: Review of methods. Journal of Rheumatology, 28, 406–412.PubMed
23.
go back to reference Beaton, D., Maxwell, L., Grosskleg, S., Shea, B., Tugwell, P. S., Bingham, C. O., III., Conaghan, P., D’Agostino, M. A., Hofstetter, C., March, L., et al. (2021). The OMERACT Handbook 2.1. Ottawa: OMERACT. Beaton, D., Maxwell, L., Grosskleg, S., Shea, B., Tugwell, P. S., Bingham, C. O., III., Conaghan, P., D’Agostino, M. A., Hofstetter, C., March, L., et al. (2021). The OMERACT Handbook 2.1. Ottawa: OMERACT.
24.
go back to reference U.S. Food and Drug Administration. Discussion Document for Patient-Focused Drug Development Public Workshop on Guidance 3: Select, Develop, or Modify Fit-for-purpose Clinical Outcome Assessments. In Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments Rockville, MD; Workshop Date October 15–16, 2018. U.S. Food and Drug Administration. Discussion Document for Patient-Focused Drug Development Public Workshop on Guidance 3: Select, Develop, or Modify Fit-for-purpose Clinical Outcome Assessments. In Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments Rockville, MD; Workshop Date October 15–16, 2018.
25.
go back to reference Strand, V., & Singh, J. A. (2010). Newer biological agents in rheumatoid arthritis: Impact on health-related quality of life and productivity. Drugs, 70, 121–145.PubMedCrossRef Strand, V., & Singh, J. A. (2010). Newer biological agents in rheumatoid arthritis: Impact on health-related quality of life and productivity. Drugs, 70, 121–145.PubMedCrossRef
26.
go back to reference Bykerk, V. P., Jamal, S., Boire, G., Hitchon, C. A., Haraoui, B., Pope, J. E., Thorne, J. C., Sun, Y., & Keystone, E. C. (2012). The Canadian Early Arthritis Cohort (CATCH): Patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. Journal of Rheumatology, 39, 2071–2080.PubMedCrossRef Bykerk, V. P., Jamal, S., Boire, G., Hitchon, C. A., Haraoui, B., Pope, J. E., Thorne, J. C., Sun, Y., & Keystone, E. C. (2012). The Canadian Early Arthritis Cohort (CATCH): Patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. Journal of Rheumatology, 39, 2071–2080.PubMedCrossRef
27.
go back to reference Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., & Ring, L. (2011). Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2–assessing respondent understanding. Value Health, 14, 978–988.PubMedCrossRef Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., & Ring, L. (2011). Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2–assessing respondent understanding. Value Health, 14, 978–988.PubMedCrossRef
28.
go back to reference Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., et al. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research, 22, 1889–1905.PubMedCrossRef Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., et al. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research, 22, 1889–1905.PubMedCrossRef
29.
go back to reference US Food and Drug Administration. (2020). Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders, vol. FDA-2020-D-1564. pp. 53820–53822. Food and Drug Administration, Health and Human Services, Docket No. FDA-2020-D-1564; Document Number:2022-01377. https://www.fda.gov/media/141565/download. US Food and Drug Administration. (2020). Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders, vol. FDA-2020-D-1564. pp. 53820–53822. Food and Drug Administration, Health and Human Services, Docket No. FDA-2020-D-1564; Document Number:2022-01377. https://​www.​fda.​gov/​media/​141565/​download.
30.
go back to reference Bartlett, S. J., Bykerk, V. P., Fautrel, B., Guillemin, F., den Broeder, A., Alten, R., Christensen, R., Choy, E., Furst, D., Hewlett, S., et al. (2017). The RA Flare Questionnaire (RA-FQ) is responsive to change in ra symptoms and impacts in clinical and observational trials. Annals of the Rheumatic Diseases, 76, 470–470. Bartlett, S. J., Bykerk, V. P., Fautrel, B., Guillemin, F., den Broeder, A., Alten, R., Christensen, R., Choy, E., Furst, D., Hewlett, S., et al. (2017). The RA Flare Questionnaire (RA-FQ) is responsive to change in ra symptoms and impacts in clinical and observational trials. Annals of the Rheumatic Diseases, 76, 470–470.
31.
go back to reference Bykerk, V. P., Bingham, C. O., Choy, E. H., Lin, D., Alten, R., Christensen, R., Furst, D. E., Hewlett, S., Leong, A., March, L., et al. (2016). Identifying flares in rheumatoid arthritis: Reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open, 2, e000225.PubMedPubMedCentralCrossRef Bykerk, V. P., Bingham, C. O., Choy, E. H., Lin, D., Alten, R., Christensen, R., Furst, D. E., Hewlett, S., Leong, A., March, L., et al. (2016). Identifying flares in rheumatoid arthritis: Reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open, 2, e000225.PubMedPubMedCentralCrossRef
32.
go back to reference Scott, I. C., & Scott, D. L. (2014). Joint counts in inflammatory arthritis. Clinical and Experimental Rheumatology, 32, 7–12. Scott, I. C., & Scott, D. L. (2014). Joint counts in inflammatory arthritis. Clinical and Experimental Rheumatology, 32, 7–12.
33.
go back to reference Sokka, T., & Pincus, T. (2009). Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheumatic Disease Clinics North America, 35, 713–722.CrossRef Sokka, T., & Pincus, T. (2009). Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheumatic Disease Clinics North America, 35, 713–722.CrossRef
34.
go back to reference Aletaha, D., & Smolen, J. S. (2007). The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Practice & Research Clinical Rheumatology, 21, 663–675.CrossRef Aletaha, D., & Smolen, J. S. (2007). The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Practice & Research Clinical Rheumatology, 21, 663–675.CrossRef
35.
go back to reference Dhaon, P., Das, S. K., Srivastava, R., & Dhakad, U. (2018). Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. International Journal of Rheumatic Diseases, 21, 1933–1939.PubMedCrossRef Dhaon, P., Das, S. K., Srivastava, R., & Dhakad, U. (2018). Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. International Journal of Rheumatic Diseases, 21, 1933–1939.PubMedCrossRef
36.
go back to reference Yun, H., Chen, L., Xie, F., Patel, H., Boytsov, N., Zhang, X., & Curtis, J. R. (2020). Do patients with moderate or high disease activity escalate rheumatoid arthritis therapy according to treat-to-target principles? results from the rheumatology informatics system for effectiveness registry of the American College of Rheumatology. Arthritis Care & Research, 72, 166–175.CrossRef Yun, H., Chen, L., Xie, F., Patel, H., Boytsov, N., Zhang, X., & Curtis, J. R. (2020). Do patients with moderate or high disease activity escalate rheumatoid arthritis therapy according to treat-to-target principles? results from the rheumatology informatics system for effectiveness registry of the American College of Rheumatology. Arthritis Care & Research, 72, 166–175.CrossRef
37.
go back to reference Goldsmith, C. H., Boers, M., Bombardier, C., & Tugwell, P. (1993). Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles OMERACT Committee. The Journal of Rheumatology, 20, 561–565.PubMed Goldsmith, C. H., Boers, M., Bombardier, C., & Tugwell, P. (1993). Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles OMERACT Committee. The Journal of Rheumatology, 20, 561–565.PubMed
38.
go back to reference Farrar, J. T., Young, J. P., Jr., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain, 94, 149–158.PubMedCrossRef Farrar, J. T., Young, J. P., Jr., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain, 94, 149–158.PubMedCrossRef
39.
go back to reference Salaffi, F., Stancati, A., Silvestri, C. A., Ciapetti, A., & Grassi, W. (2004). Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. European Journal of Pain, 8, 283–291.PubMedCrossRef Salaffi, F., Stancati, A., Silvestri, C. A., Ciapetti, A., & Grassi, W. (2004). Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. European Journal of Pain, 8, 283–291.PubMedCrossRef
40.
go back to reference Terwee, C. B., Peipert, J. D., Chapman, R., Lai, J.-S., Terluin, B., Cella, D., Griffith, P., & Mokkink, L. B. (2021). Minimal important change (MIC): A conceptual clarification and systematic review of MIC estimates of PROMIS measures. Quality of Life Research, 30, 2729–2754.PubMedPubMedCentralCrossRef Terwee, C. B., Peipert, J. D., Chapman, R., Lai, J.-S., Terluin, B., Cella, D., Griffith, P., & Mokkink, L. B. (2021). Minimal important change (MIC): A conceptual clarification and systematic review of MIC estimates of PROMIS measures. Quality of Life Research, 30, 2729–2754.PubMedPubMedCentralCrossRef
41.
go back to reference Starfield, B., Wray, C., Hess, K., Gross, R., Birk, P. S., & D’Lugoff, B. C. (1981). The influence of patient-practitioner agreement on outcome of care. American Journal of Public Health, 71, 127–131.PubMedPubMedCentralCrossRef Starfield, B., Wray, C., Hess, K., Gross, R., Birk, P. S., & D’Lugoff, B. C. (1981). The influence of patient-practitioner agreement on outcome of care. American Journal of Public Health, 71, 127–131.PubMedPubMedCentralCrossRef
42.
go back to reference Rohekar, G., & Pope, J. (2009). Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. Journal of Rheumatology, 36, 2178–2182.PubMedCrossRef Rohekar, G., & Pope, J. (2009). Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. Journal of Rheumatology, 36, 2178–2182.PubMedCrossRef
43.
go back to reference Desthieux, C., Hermet, A., Granger, B., Fautrel, B., & Gossec, L. (2016). Patient-physician discordance in global assessment in rheumatoid arthritis: A systematic literature review with meta-analysis. Arthritis Care Res (Hoboken), 68, 1767–1773.PubMedCrossRef Desthieux, C., Hermet, A., Granger, B., Fautrel, B., & Gossec, L. (2016). Patient-physician discordance in global assessment in rheumatoid arthritis: A systematic literature review with meta-analysis. Arthritis Care Res (Hoboken), 68, 1767–1773.PubMedCrossRef
44.
go back to reference Beaton, D. E., Bombardier, C., Katz, J. N., Wright, J. G., Wells, G., Boers, M., Strand, V., & Shea, B. (2001). Looking for important change/differences in studies of responsiveness. OMERACT MCID Working. Group Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol., 28, 400–405.PubMed Beaton, D. E., Bombardier, C., Katz, J. N., Wright, J. G., Wells, G., Boers, M., Strand, V., & Shea, B. (2001). Looking for important change/differences in studies of responsiveness. OMERACT MCID Working. Group Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol., 28, 400–405.PubMed
45.
go back to reference Curtis, J. R., Yang, S., Chen, L., Pope, J. E., Keystone, E. C., Haraoui, B., Boire, G., Thorne, J. C., Tin, D., Hitchon, C. A., et al. (2015). Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients. Arthritis Care Res (Hoboken), 67, 1345–1353.PubMedCrossRef Curtis, J. R., Yang, S., Chen, L., Pope, J. E., Keystone, E. C., Haraoui, B., Boire, G., Thorne, J. C., Tin, D., Hitchon, C. A., et al. (2015). Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients. Arthritis Care Res (Hoboken), 67, 1345–1353.PubMedCrossRef
46.
go back to reference Anderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., Saag, K. G., O’Dell, J. R., & Kazi, S. (2012). Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken), 64, 640–647.PubMedCrossRef Anderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., Saag, K. G., O’Dell, J. R., & Kazi, S. (2012). Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken), 64, 640–647.PubMedCrossRef
47.
go back to reference Bykerk, V. P., Akhavan, P., Hazlewood, G. S., Schieir, O., Dooley, A., Haraoui, B., Khraishi, M., Leclercq, S. A., Legare, J., Mosher, D. P., et al. (2012). Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Journal of Rheumatology, 39, 1559–1582.PubMedCrossRef Bykerk, V. P., Akhavan, P., Hazlewood, G. S., Schieir, O., Dooley, A., Haraoui, B., Khraishi, M., Leclercq, S. A., Legare, J., Mosher, D. P., et al. (2012). Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Journal of Rheumatology, 39, 1559–1582.PubMedCrossRef
48.
go back to reference Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56, 395–407.PubMedCrossRef Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56, 395–407.PubMedCrossRef
Metagegevens
Titel
“From Where I Stand”: using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ)
Auteurs
Susan J. Bartlett
Vivian P. Bykerk
Orit Schieir
Marie-France Valois
Janet E. Pope
Gilles Boire
Carol Hitchon
Glen Hazlewood
Louis Bessette
Edward Keystone
Carter Thorne
Diane Tin
Clifton O. Bingham III
CATCH Investigators
Publicatiedatum
08-09-2022
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03227-7

Andere artikelen Uitgave 5/2023

Quality of Life Research 5/2023 Naar de uitgave